Finally, CD34+ normal cells were only modestly affected by treatment with PIK-III or Lys05 compared to CD34+ CML cells, suggesting a potential therapeutic window for autophagy inhibition as a CML therapy. This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.